HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Host-mediated inhibition of rat bladder cancer growth by cyclophosphamide and purine salvage pathway-related enzyme activity of lymphocytes.

Abstract
In ACI/N rats pretreated with cyclophosphamide (CY) growth of the bladder cancer, BC-47, and adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) activities in lymphocytes were investigated to clarify the possible antitumor effect via the immune system of the chemotherapeutic agent. A single dose of 50 mg/kg of CY with the tumor implantation 3 days later gave rise to tumor regression following temporary progression around day 15 and significant increase of peripheral lymphocytes with higher PNP activity on days 7 to 10 of the tumor implantation. In the thymus such lymphocytes increased 3 days earlier. The antitumor effect was not demonstrated in athymic nude mice. In the light of the results and elimination of suppressor T precursors by CY, it was postulated that T lymphocytes with higher PNP activity act as effector cells in the antitumor immunity whereas suppressor T precursors belong to the cell population with lower PNP activity.
AuthorsT Iwaguchi, M Nakamura, H Kitagawa
JournalThe Japanese journal of experimental medicine (Jpn J Exp Med) Vol. 54 Issue 5 Pg. 201-6 (Oct 1984) ISSN: 0021-5031 [Print] Japan
PMID6442929 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cyclophosphamide
  • Pentosyltransferases
  • Purine-Nucleoside Phosphorylase
  • Nucleoside Deaminases
  • Adenosine Deaminase
Topics
  • Adenosine Deaminase (blood)
  • Animals
  • Cyclophosphamide (therapeutic use)
  • Kinetics
  • Leukocyte Count
  • Lymphocytes (enzymology, immunology)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Neoplasm Transplantation
  • Nucleoside Deaminases (blood)
  • Pentosyltransferases (blood)
  • Purine-Nucleoside Phosphorylase (blood)
  • Rats
  • Rats, Inbred ACI
  • T-Lymphocytes (immunology)
  • Urinary Bladder Neoplasms (drug therapy, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: